Evogene Ltd.

EVGN Healthcare Biotechnology

In the quarter to June 2026, revenue fell 35.0%, EPS grew 77.4% and free cash flow grew 17.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

0.39 0.01 −2.50%
Market cap
$6.3M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
4/9
Altman Z
−20.48
Beneish M
n/a
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
2 3 3 4 3 3 4 4 3 4
Altman Z-Score
7.95 3.80 0.29 (1.19) 1.37 (1.25) (5.89) (6.98) (10.70) (20.48)
P/S ratio
19.76 26.35 29.19 51.99 127.26 71.30 17.96 7.08 1.91 2.25
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
11.55 7.80 1.95 0.54 (2.63) (2.10) (11.33) (15.04) (24.48) (45.11)
Beneish M-Score
(3.38) (2.69) (2.76) 344.94 (2.53) (2.29) (3.07) (1.38) (2.43) —
P/Operating CF
(30.54) (24.98) 12.77 (8.40) (19.26) (8.20) (13.33) (6.74) (2.34) (3.22)
P/B ratio
1.48 1.28 1.01 0.65 2.33 1.05 0.86 1.39 0.72 0.72
EV/Sales
6.28 5.13 (1.99) (10.27) 80.88 13.38 (3.15) 1.57 (0.84) (1.12)
EV/EBITDA
0.00 0.00 0.18 0.42 0.00 0.00 0.22 0.00 0.27 0.37
EV/FCF
(3.29) (1.05) 0.42 0.42 (4.17) (0.49) 0.21 (0.40) 0.23 0.32
Current Ratio
17.13 15.61 10.22 8.53 5.36 8.27 6.71 4.96 1.15 4.54
Net Debt/EBITDA
4.69 3.62 3.03 2.55 2.18 1.88 1.45 1.30 0.90 1.12
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
(20.51%) (26.60%) (34.69%) (32.78%) (39.92%) (46.21%) (54.25%) (75.24%) (75.75%) (63.29%)
ROA
(18.79%) (24.01%) (30.46%) (27.85%) (32.63%) (37.50%) (40.23%) (44.54%) (36.24%) (28.33%)
ROIC
0.00% 0.00% 0.00% (99.16%) (179.23%) (202.49%) 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(21.59%) (28.58%) (38.99%) (39.49%) (52.86%) (53.36%) (76.93%) (79.65%) (350.89%) (65.27%)
Average Days of Receivables
74.34 111.84 213.32 1,042.65 1,261.36 1,150.73 398.78 215.51 206.49 178.28
Earnings Yield
(15.16%) (23.34%) (41.41%) (46.71%) (17.45%) (42.07%) (87.67%) (60.92%) (166.31%) (106.36%)
Free Cash Flow Yield
(9.67%) (18.54%) (16.42%) (47.43%) (15.26%) (38.55%) (82.60%) (55.95%) (190.70%) (156.55%)
Free Cash Flow per Share
(4.91) (6.43) (6.03) (7.21) (7.17) (6.32) (6.03) (4.87) (3.57) (1.72)
Book value per Share
34.31 27.02 19.53 23.38 20.20 15.69 8.44 6.25 2.60 1.52
Free Cash Flow
(12.50) (16.52) (15.53) (18.57) (20.20) (25.56) (24.85) (22.34) (20.32) (13.56)
EV/EBIT
0.00 0.00 0.17 0.37 0.00 0.00 0.20 0.00 0.25 0.31
Other line items

Show all line items

Columns are period end dates